MD Anderson Cancer Center at Cooper is participating in a clinical research study to determine if certain breast cancer patients who respond positively to neoadjuvant systemic therapy can be treated without surgery.
According to Cooper University Health Care, the study is being done in conjunction with The University of Texas MD Anderson Cancer Center and is being led by principal investigator Dr. Henry Kuerer, professor in the Department of Breast Surgical Oncology at MD Anderson.
Neoadjuvant chemotherapy is the administration of intravenous therapeutic agents to reduce a tumor in advance of another treatment such as surgery. Researchers believe some patients with certain kinds of breast cancer who have an extraordinary response to pre-surgery chemotherapy can benefit from this type of treatment without surgery and not require a lumpectomy.
“This study has the potential to spare patients from surgery and its attendant risks and potential complications when they may not derive a significant benefit. This study supports the national initiative toward minimizing overtreatment of breast cancer,” Dr. Catherine Loveland-Jones, attending surgeon at MD Anderson at Cooper, said in a prepared statement.
The trial is open to women with tumors that are less than 5 centimeters and either triple-negative and/or Her2-neu positive.